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Synthesis of new 1-aryl-3-substituted propanol derivatives followed by structure-activity relationship, in
silico drug-likeness, cytotoxicity, genotoxicity, in silico metabolism, in silico pharmacophore modeling,
and in vivo studies led to the identiﬁcation of compounds 22 and 23 with signiﬁcant in vitro anti-
plasmodial activity against drug sensitive (D6 IC50  0.19 mM) and multidrug resistant (FCR-3
IC50  0.40 mM and C235 IC50  0.28 mM) strains of Plasmodium falciparum. Adequate selectivity index
and absence of genotoxicity was also observed. Notably, compound 22 displays excellent parasitemia
reduction (98 ± 1%), and complete cure with all treated mice surviving through the entire period with no
signs of toxicity. One important factor is the agreement between in vitro potency and in vivo studies.
Target exploration was performed; this chemotype series exhibits an alternative antimalarial
mechanism.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Malaria, a major tropical disease for which no long-term sus-
tainable treatment is available, continues to affect large parts of the
world. According to the latest World Malaria Report, 3.2 billion
people in 96 countries are at risk of being infected. In 2015 alone,
214 million cases were reported globally resulting in an estimatedd Pharmaceutical Chemistry,
al Health (ISTUN), University
pain.
nd Biomedical Sciences, Col-
ty, Clovis, CA, USA.
Ltd on behalf of Australian Society f438,000 deaths mainly consisting of African children and pregnant
women (WHO, 2015). This life-threatening disease is caused by
Plasmodium species with Plasmodium falciparum (P. falciparum)
being the most deadly. Currently, ﬁrst-line therapy includes
artemisinin-based combination therapies (ACT) (Delves et al., 2012;
Wells et al., 2015); however, in recent years parasite resistance
against artemisinin and its derivatives has emerged and spread
along the Cambodia-Thailand border (Ashley et al., 2014; Tun et al.,
2015). To address this challenge, new antimalarial entities are
needed. Although recent efforts in antimalarial drug discovery have
focused on new targets, nonclassical chemical scaffolds, and vac-
cines (Biamonte et al., 2013; Barnett and Guy, 2014; Wells et al.,
2015), extensive studies on classical antimalarial chemotypes or
drug repurposing are needed due to the high cost and time requiredor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
M. Quiliano et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 184e198 185in the drug discovery and development process (Andrews et al.,
2014; Biamonte, 2014).
One classic antimalarial chemotype present in potent antima-
larial drugs, including quinine (1), meﬂoquine (2), lumefantrine (3),
and halofantrine (4), is the arylamino alcohol (ß-amino or g-amino
alcohol moiety). The structural requirements for antiplasmodial
activity include the presence of an aromatic and amino alcohol
portion linked by a carbon chain of two or three atoms in length
(Bhattacharjee and Karle, 1996) (Fig. 1). Based on this anti-
plasmodial pharmacophore, antimalarial amino alcohols continue
to attract the interest of various research groups due to their high
biological activity and ADMET values. Representative studies of the
ß-amino alcohol moiety include the works of Guy et al. who per-
formed the optimization of propafenone analogues (Lowes et al.,
2011, 2012) as a product of high throughput screening (Weisman
et al., 2006), and Smith and Chibale et al. who developed totarol
(Clarkson et al., 2003; Tacon et al., 2012) and chalcone (Hans et al.,
2010), respectively, as natural product-like hybrid derivatives. In
addition, meﬂoquine and 4-aminoquinoline derivatives are valid
synthetic approaches explored by Milner et al. (2010) and
Kobarfard et al. (2012), respectively, among other studies (Robin
et al., 2007; D'hooghe et al., 2011). However, there are only a few
examples of the g-amino alcohol moiety reported in the last thir-
teen years (D'hooghe et al., 2009; Perez-Silanes et al., 2009; Men-
doza et al., 2011; Quiliano and Aldana, 2013). D'hooghe et al. (2009)
reported a wide range of antiplasmodial activity against the chlo-
roquine sensitive P. falciparum strain D10; however, submicromolar
values were not reached (6 mM  IC50  175 mM). Thus, further
studies on the unexplored g-moiety as a source of new antimalarial
drugs are needed.
Our research on g-amino alcohols explored the structure-
activity relationship (SAR) of 1-aryl-3-susbtituted propanol de-
rivatives (APD) with promising results (Perez-Silanes et al., 2009;
Mendoza et al., 2011; Quiliano and Aldana, 2013). Initial SAR
studies showed that all of the aryl-ketone derivatives were inactive
against 3D7, NF54, and FCR-3 strains of P. falciparum (Perez-Silanes
et al., 2009; Mendoza et al., 2011). In contrast, APD were active
against 3D7 (0.19  IC50  0.38 mM) (Perez-Silanes et al., 2009),
NF54 (1.3  IC50  8 mM) (Mendoza et al., 2011), and FCR-3Fig. 1. Antimalarial drugs with amino alcohol moiety as a pharmacopho(0.5  IC50  10 mM) (Mendoza et al., 2011) strains of
P. falciparum. However, low parasitemia reduction (65%) was
observed in the in vivo Plasmodium berghei (P. berghei) mouse
model. Interestingly, linker reduction in one carbon atom between
the alcohol and amine portion (g-to ß-amino alcohol) in APD
reduced the activity by half. Previous, in silico studies proposed
plasmepsin II (PM2) as a putative target for APD (Mendoza et al.,
2011), but has yet to be conﬁrmed experimentally. Nonetheless,
more studies with APD are necessary to be validated as potential
antimalarial hits (MMV, 2008).
Thus, exploration and development of APD as antimalarials re-
quires (1) expanding SAR studies, (2) generating additional ana-
logues with high potency against both chloroquine sensitive and
multidrug resistant strains of P. falciparum, (3) improving para-
sitemia reduction in the P. berghei mouse model, (4) establishing a
safe toxicological proﬁle, and (5) exploring biological targets in
P. falciparum.
In this study, we expanded the chemical scope in the antima-
larial framework by preparing new APD for testing their anti-
plasmodial activity in vitro against P. falciparum (sensitive and
resistant strains) and in vivo against P. berghei. Chiral separation and
enantiomeric testingwere also conducted. Further, cytotoxicity and
genotoxicity studies were performed on active compounds and
potential metabolites. Since target validation is a crucial step in the
drug discovery process, APD compounds were evaluated for their
ability to inhibit both the PM2 enzyme and the hemozoin forma-
tion pathway. Finally, pharmacophore modeling studies were per-
formed on APD.
2. Material and methods
2.1. Synthesis of APD compounds
The methods used for synthesizing the ﬁnal compounds
(14e26) are presented in Schemes 1 and 2. The synthetic method
has been published previously (Perez-Silanes et al., 2009; Mendoza
et al., 2011). The starting arylamines 2-nitro-4-triﬂuoromethyl
phenyl piperazine, 4-(4-ﬂuorophenyl)-1,2,3,6-tetrahydropyridine
and 4-triﬂuoromethyl phenyl piperazine were commerciallyre: (1) quinine; (2) meﬂoquine; (3) lumefantrine; (4) halofantrine.
Scheme 1. Synthesis of arylamines not commercially available.
Scheme 2. Synthesis of arylamino alcohols 14e26.
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sized using the corresponding BOC-amine (I) and 2-ﬂuoro-4-
nitrobenzotriﬂuoride by an Ar-SN’ reaction via Meisenheimer
complex formation and subsequent removal of the BOC-group with
HCl and acetic acid (Scheme 1). All methyl ketone precursors (V)
were commercially available. The ketone intermediates (b-amino
ketones) (1e13) were prepared by condensation of the corre-
sponding methyl ketone (V) with the different aryl amines (IV) via
Mannich reaction (Scheme 2). The hydroxyl derivatives (g-amino
alcohols) (14e26) were obtained by reduction of the corresponding
carbonyl group with NaBH4 in methanol (Scheme 2).
2.2. Experimental section
2.2.1. Reagents and instruments
Chemical reagents and solvents were purchased from com-
mercial companies and were used without further puriﬁcation. All
of the synthesized ﬁnal compounds were chemically characterized
by thin layer chromatography (TLC), melting point (mp) and proton
and carbon nuclear magnetic resonance (1H NMR and 13C NMR)
spectra as well as by elemental microanalysis. Purity was deter-
mined by high performance liquid chromatography (HPLC). Final
compounds were conﬁrmed to have 96% purity. 1H NMR and 13CNMR spectra were recorded on a Bruker 400 Ultrashield (Rhein-
stetten, Germany) operating at 400 and 100 MHz, respectively,
using tetramethylsilane (TMS) as the internal standard and chlo-
roform (CDCl3) or dimethyl sulfoxide-d6 (DMSO-d6) as solvents. The
chemical shifts are reported in ppm (d) and the coupling constant
(J) values are given in Hertz (Hz). Elemental microanalyses were
obtained on an Elemental Analyzer (LECO CHN-900, Michigan,
USA) from vacuum-dried samples. The analytical results for C, H,
and N were within ±0.4 of the theoretical values. Alugram SIL G/
UV254 (Layer: 0.2 mm) (Macherey-Nagel, Germany) was used for
TLC and silica gel 60 (0.040e0.063 mm and 0.063e0.200 nm) was
used for column chromatography (Merck). Some ﬁnal derivatives
were puriﬁed by automated ﬂash chromatography with a binary
gradient of dichloromethane (DCM) (synthesis grade SDS-Carlo
Erba Reactifs, France) and methanol (MeOH) (Panreac Química
S.A.) and UV variable dual-wavelength detection. The chromatog-
raphy was developed using the CombiFlash® Rf (Teledyne Isco,
Lincoln. USA) with DCM/MeOH as solvents and a normal phase of
12 g Flash Column (RediSep® Rf Columns by Teledyne Isco, Inc.,
USA). HPLC experiments were developed on an Ultimate 3000
Chromatograph (Dionex) with Chromeleon v.6.8 software. The
measurements were performed using an RP 18 column (Lichros-
pher 100 RP 18 E.C. 5 mm; 10  0.46 cm; Teknokroma) as the
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(80:20) as the mobile phase. The retention times (tR) are expressed
in minutes and the reference wavelength is set at 254 nm. Com-
pounds II and III were synthesized as previously described (Perez-
Silanes et al., 2009; Mendoza et al., 2011).
2.2.2. General synthetic methods
2.2.2.1. General method 1 for the synthesis of ketone derivatives
(1e13). The corresponding substituted aryl methyl ketone (V) (1.0
equiv) and the aryl amine (IV) (1.0 equiv) was dissolved in 1,3-
dioxolane (1.4%) and concentrated HCl (1 mL) was added until pH
1e2 was reached. The resulting mixture was heated at reﬂux for
1e2 h. NaOH (2 M) was then added (50 mL) and the product was
extracted with DCM (3  50 mL). The organic phase was dried with
anhydrous Na2SO4, ﬁltered, and evaporated to dryness under
reduced pressure. The residue was puriﬁed by column chroma-
tography on silica gel using DCM/MeOH 95:5 (v/v) as eluent or
automated ﬂash chromatography eluting with DCM/MeOH 99:1 (v/
v). In other cases, the hydrochloride salt was prepared by adding a
hydrogen chloride ethereal solution to the stirred compounds.
Spectral data for selected ketone derivatives is shown at
Supplementary Data section.
2.2.2.2. General method 2 for the synthesis of hydroxyl derivatives
(14e26). Sodium borohydride (3.0 equiv) was added dropwise to a
pre-cooled suspension (0 C) of the corresponding ketone (V) (1.0
equiv) in MeOH over a period of 30e60 min. The solvent was
removed under reduced pressure and the residue was dissolved in
DCM (40mL) and thenwashed with water (3 30 mL). The organic
phase was dried with anhydrous Na2SO4 and ﬁltered. After evap-
orating the solvent to dryness under reduced pressure, the com-
pound was puriﬁed by column chromatography (SP: silica gel)
eluting with DCM/MeOH 99:1 (v/v) or automated ﬂash chroma-
tography eluting with DCM/MeOH 99:1 (v/v). Selected compounds
were converted to hydrochloride salts by adding a hydrogen chlo-
ride ethereal solution to the stirred compounds.
2.2.2.3. 1-(5-ﬂuorobenzo[b]thiophen-3-yl)-3-[4-(4-nitro-2-
triﬂuoromethylphenyl)piperazin-1-yl] propan-1-ol (14). Yield: 21%,
mp 140-142 C. 1H NMR (DMSO-d6, 400MHz) d ppm: 8.46, 8.49 (dd,
1H, J ¼ 9.0 Hz, J ¼ 2.5 Hz); 8.42 (d, 1H, J ¼ 2.6 Hz); 8.04 (q, 1H,
J¼ 8.8 Hz, J¼ 5.1 Hz); 7.82,7.83 (dd, 1H, J¼ 10.3 Hz, J¼ 2.4 Hz); 7.77
(s, 1H); 7.65 (d, 1H, J ¼ 9.0 Hz); 7.27 (dt, 1H, J ¼ 8.9 Hz, J ¼ 2.4 Hz);
5.82 (br s, 1H); 5.05 (br s, 1H); 3.64 (d, 2H); 3.42e3.50 (m, 6H); 3.17
(br s, 2H); 2.23,2.30 (dd, 2H) ppm. 13C NMR (DMSO-d6, 100 MHz) d:
162.07; 159.65; 156.10; 151.77; 143.58; 140.66 (d, J¼ 4.6 Hz); 139.18
(d, J ¼ 8.4 Hz); 136.75; 129.60; 126.26; 125.43 (d, J ¼ 9.0 Hz);
125.13; 124.56 (d, J ¼ 6.8 Hz); 113.78 (d, J ¼ 25.4 Hz); 109.15 (d,
J ¼ 23.6 Hz); 66.45; 54.19; 51.92 (2C); 50.05 (2C); 31.81 ppm. Anal.
Calcd for C22H21N3F4O3S: C, 54.65%; H, 4.38%; N, 8.64%; Found: C,
54.83%; H, 4.44%; N, 8.99%.
2.2.2.4. Hydrochloride of 1-(5-ﬂuorobenzo[b]thiophen-3-yl)-3-[4-(2-
nitro-4-triﬂuoromethyl phenyl)piperazin-1-yl] propan-1-ol (15).
Yield: 20%, mp 196-198 C. 1H NMR (400 MHz, DMSO-d6) d: 8.20 (s,
1H), 8.02 (dd, 1H, J ¼ 8.9 Hz, 5.1 Hz), 7.90 (d, 1H, J ¼ 8.4 Hz), 7.77 (d,
1H, J ¼ 10.2 Hz), 7.72 (s, 1H), 7.49 (d, 1H, J ¼ 8.5 Hz), 7.26 (dt, 1H,
J ¼ 9.1 Hz, 8.8 Hz, 2.2 Hz), 5.00 (br s, 1H), 3.70 (br s, 2H), 3.24 (br s,
4H), 2.92 (bs, 4H), 2.06 (br s, 2H) ppm. 13C NMR (DMSO-d6,
100 MHz) d: 161.98; 159.61; 147.87; 140.78; 139.33 (d, J ¼ 9.0 Hz);
136.73; 131.20 (d, J ¼ 3.1 Hz); 126.02; 125.68; 125.41 (d, J ¼ 9.1 Hz);
124.60 (q, J¼ 4.1 Hz); 122.98; 122.74; 113.71 (d, J¼ 25.4 Hz); 109.06
(d, J ¼ 23.2 Hz); 74.12; 66.99; 54.88 (2C); 52.35 (2C); 48.23 ppm.
Anal. Calcd for C22H21N3F4O3S.HCl: C, 50.81%; H, 4.23%; N, 8.08%;
Found: C, 51.20%; H, 3.85%; N, 8.11%.2 . 2 . 2 . 5 . 1 - ( 5 -ﬂuo ro b en z o [ b ] t h i o ph en - 3 - y l ) - 3 - ( 4 - ( 4 -
triﬂuoromethylphenyl)piperazin-1-yl) propan-1-ol (16). Yield: 15%,
mp 158-160 C. 1H NMR (400 MHz, CDCl3) d: 7.80 (br s, 1H),
7.50e7.54 (m, 4H), 7.10e7.15 (m, 1H), 6.96 (d, 2H, J ¼ 8.4 Hz), 5.32
(dd, 1H, J ¼ 4.1 Hz, 6.7 Hz), 3.45 (br s, 4H), 2.93e2.94 (m, 3H), 2.82
(br s, 3H), 2.21 (bs, 2H) ppm. 13C NMR (CDCl3, 100 MHz) d: 162.20;
159.80; 153.44; 139.83 (d, J ¼ 4.4 Hz); 138.71 (d, J ¼ 9.1 Hz); 136.76
(d, J ¼ 1.4 Hz); 126.88 (2C, q, J ¼ 3.8 Hz); 126.44; 124.64; 124.41(d,
J ¼ 9.4 Hz); 115.19 (2C); 113.51 (d, J ¼ 25.2 Hz); 108.29 (d,
J ¼ 23.4 Hz); 71.97; 57.57; 53.40 (2C); 48.51 (2C); 31.87 ppm. Anal.
Calcd for C22H22N2F4OS: C, 60.26%; H, 5.06%; N, 6.39%; Found: C,
60.30%; H, 4.95%; N, 6.24%.
2.2.2.6. 1-(5-ﬂuorobenzo[b]thiophen-3-yl)-3-[4-(4-nitro-2-
triﬂuoromethylphenyl)-1,4-diazepan-1-yl]propan-1-ol (17).
Yield: 25%, mp 110-111 C. 1H NMR (400 MHz, CDCl3) d: 8.54 (s, 1H),
8.28 (dd, 1H, J¼ 9.2 Hz, 2.7 Hz), 7.80 (dd, 1H, J¼ 8.8 Hz, 5.0 Hz), 7.51
(dd, 1H, J ¼ 9.8 Hz, 1.5 Hz), 7.50 (s, 1H), 7.22 (d, 1H, J ¼ 9.2 Hz), 7.12
(dd, 1H, J ¼ 8.8 Hz, 2.4 Hz), 5.62 (br s, 2H), 5.30 (t, 1H, J ¼ 5.7 Hz),
3.54 (br s, 2H), 2.98e2.99 (m, 2H), 2.87e2.93 (m, 4H), 2.08 (br s, 4H)
ppm. 13C NMR (CDCl3, 100 MHz) d: 162.18; 159.78; 157.28; 151.76;
140.69; 139.90 (d, J ¼ 4.7 Hz); 138.68 (d, J ¼ 8.9 Hz); 136.76 (d,
J ¼ 1.3 Hz); 127.92; 125.78 (q, J ¼ 5.9 Hz); 124.62; 124.40 (d,
J ¼ 9.4 Hz); 121.74; 113.49 (d, J ¼ 25.0 Hz); 108.26 (d, J ¼ 23.4 Hz);
72.07; 57.69; 56.35; 55.68; 55.37; 54.64; 32.60; 28.04 ppm. Anal.
Calcd for C23H23N3F4O3S: C, 55.53%; H, 4.66%; N, 8.45%; Found: C,
55.15%; H, 4.64%; N, 8.26%.
2.2.2.7. 1-(5-ﬂuorobenzo[b]thiophen-3-yl)-3-[1-(4-nitro-2-
triﬂuoromethylphenyl)piperidin-4-yl]amino)propan-1-ol (18).
Yield: 37%, mp 140-142 C. 1H NMR (400 MHz, CDCl3) d: 8.53 (br s,
1H), 8.33 (dd, 1H, J¼ 8.5 Hz, 1.8 Hz), 7.79 (dd. 1H, J ¼ 8.2 Hz, 3.1 Hz),
7.52 (s, 1H), 7.50 (dd, 1H, J ¼ 8.5 Hz, 4.9 Hz), 7.29 (d, 1H, J ¼ 8.6 Hz),
7.12 (t, 1H, J¼ 7.7 Hz), 5.30 (d,1H, J¼ 7.7 Hz), 3.42 (d, 2H, J¼ 9.0 Hz),
3.13 (br s, 2H), 2.95 (t, 2H, J ¼ 9.7 Hz), 2.75 (br s, 1H), 2.11 (br s, 3H),
1.95e1.97 (m, 1H), 1.56e1.71 (m, 2H) ppm. 13C NMR (CDCl3,
100 MHz) d: 162.16; 159.76; 157.67 (d, J ¼ 1.4 Hz); 151.76; 142.37;
140.10 (d, J ¼ 4.4 Hz); 138.67 (d, J ¼ 9.5 Hz); 136.78 (d, J ¼ 1.2 Hz);
128.18; 125.11 (q, J ¼ 5.7 Hz); 124.65; 124.38 (d, J ¼ 9.4 Hz); 122.71;
113.43 (d, J ¼ 25.0 Hz); 108.25 (d, J ¼ 23.4 Hz); 72.13; 54.52; 52.34
(2C); 45.72; 35.80; 32.94 (2C) ppm. Anal. Calcd for C23H23N3F4O3S:
C, 55.53%; H, 4.66%; N, 8.45%; Found: C, 55.55%; H, 4.62%; N, 8.44%.
2.2.2.8. 3-[4-(4-ﬂuorophenyl)-3,6-dihydropyridin-1(2H)-yl]-1-
(naphthalen-2-yl)propan-1-ol (19). Yield:23%, mp 127-129 C. 1H
NMR (400 MHz, CDCl3) d: 7.91 (s, 1H), 7.87 (dd, 1H, J ¼ 7.8 Hz,
2.3 Hz), 7.85 (d, 2H, J ¼ 8.3 Hz), 7.51 (dd, 1H, J ¼ 7.4 Hz, 1.6 Hz),
7.45e7.50 (m, 2H), 7.37 (dd, 2H, J ¼ 8.7 Hz, 5.4 Hz), 7.04 (t, 2H,
J ¼ 8.7 Hz), 6.02 (s, 1H), 5.17 (br s, 1H), 3.31 (d, 2H, J ¼ 16.7 Hz),
2.72e2.96 (m, 4H), 2.64 (s, 2H), 1.99e2.12 (m, 2H) ppm. 13C NMR
(CDCl3, 100 MHz) d: 163.81; 161.35; 142.52; 136.88 (d, J ¼ 2.9 Hz);
134.67; 133.82; 133.13; 128.36 (d, J¼ 4.4 Hz); 128.06; 126.86 (2C, d,
J ¼ 7.9 Hz); 126.40; 125.95; 124.48 (2C, d, J ¼ 12.8 Hz); 121.08;
115.60 (2C, d, J ¼ 21.3 Hz); 75.80; 56.89; 53.55; 50.42; 34.29;
28.27 ppm. Anal. Calcd for C24H24NFO.½H2O: C, 77.74%; H, 6.74%; N,
3.77%; Found: C, 77.87%; H, 6.82%; N, 3.40%.
2.2.2.9. 3-[4-(4-ﬂuorophenyl)-3,6-dihydropyridin-1(2H)-y])-1-(4-
(triﬂuoromethylphenyl)propan-1-ol (20). Yield: 40%, mp 116-117 C.
1H NMR (400 MHz, DMSO-d6) d: 7.68 (d, 2H, J ¼ 8.1 Hz), 7.57 (d, 2H,
J ¼ 7.9 Hz), 7.47 (dd, 2H, J ¼ 8.4 Hz, 5.6 Hz), 7.15 (t, 2H, J ¼ 8.8 Hz),
6.12 (s, 1H), 5.70 (br s, 1H), 4.75e4.80 (m, 1H), 3.08 (s, 2H), 2.62 (t,
2H, J ¼ 5.5 Hz), 2.45e2.50 (m, 4H), 1.81 (dd, 2H, J ¼ 13.7 Hz, 7.3 Hz)
ppm. 13C NMR (DMSO-d6, 100 MHz) d: 160.98; 151.87; 137.40 (d,
J ¼ 3.0 Hz); 133.82; 128.30; 127.99; 127.30 (2C); 127.22; 126.64;
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55.32; 53.60; 50.74; 36.96; 28.36 ppm. Anal. Calcd for C21H21NF4O:
C, 66.49%; H, 5.54%; N, 3.69%; Found: C, 66.11%; H, 5.67%; N, 3.81%.
2.2.2.10. Hydrochloride of 1-(4-ﬂuoronaphthalen-1-yl)-3-(4-(4-(tri-
ﬂuoromethylphenyl) piperazin-1-yl) propan-1-ol (21). Yield; 45%,
mp 174-175 C. 1H NMR (400MHz, DMSO-d6) d: 11.12 (br s,1H), 8.29
(d, 1H, J¼ 8.8 Hz), 8.10 (d, 1H, J¼ 6.6 Hz), 7.67 (br s, 3H), 7.56 (d, 2H,
J ¼ 8.4 Hz), 7.36 (dd, 1H, J ¼ 8.2 Hz, 9.7 Hz), 7.13 (d, 2H, J ¼ 8.1 Hz),
5.90 (br s, 1H), 5.41 (d, 1H, J ¼ 7.5 Hz), 3.97 (br s, 2H), 3.20e3.30 (m,
6H), 3.55 (br s, 2H), 2.21 (d, 2H) ppm. 13C NMR (DMSO-d6, 100 MHz)
d: 159.34; 152.87; 137.93; 129.53; 127.72; 127.21 (2C); 126.81;
125.01; 124.62; 124.34; 123.92 (d, J ¼ 9.1 Hz); 123.67; 121.37 (d,
J¼ 6.0 Hz); 115.76 (2C); 109.94; 67.62; 54.46; 51.64 (2C); 45.23 (2C);
32.94 ppm. Anal. Calcd for C24H24N2F4O.HCl: C, 61.47%; H, 5.39%; N,
5.98%; Found: C, 61.35%; H, 5.02%; N, 5.96%.
2.2.2.11. 1-(4-Fluoronaphthalen-1-yl)-3-((1-(4-nitro-2-(tri-
ﬂuoromethyl)phenyl)piperidin-4-yl) amino) propan-1-ol (22).
Yield: 90%, mp 93-95 C. 1H NMR (400 MHz CDCl3) d: 8.53 (d, 1H,
J ¼ 2.7 Hz), 8.33 (dd, 1H, J ¼ 9.0 Hz, 2.7 Hz), 8.16 (dd, 1H, J ¼ 7.2 Hz,
3.3 Hz), 8.04 (d, 1H, J ¼ 7.8 Hz), 7.67e7.72 (m, 1H), 7.53e7.61 (m,
2H), 7.27e7.30 (m, 1H), 7.17 (dd, 1H, J ¼ 10.2 Hz, 8.1 Hz), 5.71 (dd,
1H, J ¼ 8.2 Hz, 2.3 Hz), 3.42 (d, 2H), 3.08e3.15 (m, 1H), 3.00e3.03
(m, 1H), 2.98 (t, 2H, J ¼ 11.5 Hz), 2.75e2.84 (m, 1H), 2.12 (d, 1H,
J ¼ 12.7 Hz), 2.15e2.23 (m, 2H), 1.86e2.01 (m, 1H), 1.68e1.83 (m,
2H) ppm. 13C NMR (CDCl3, 100 MHz) d: 159.75; 157.66; 157.26;
142.39; 136.42 (d, J ¼ 3.7 Hz); 131.74 (d, J ¼ 4.2 Hz); 128.18; 127.16;
126.06; 125.12 (d, J¼ 5.4 Hz); 124.66; 124.22; 123.33 (d, J¼ 2.8 Hz);
123.24 (d, J ¼ 8.5 Hz); 122.72; 121.76 (d, J ¼ 5.8 Hz); 109.25 (d,
J¼ 19.5 Hz); 72.58; 54.56; 52.32 (2C); 45.74; 36.95; 32.88 (2C) ppm.
Anal. Calcd for C25H25N3F4O3: C, 61.10%; H, 5.09%; N, 8.55%; Found:
C, 60.77%; H, 5.43%; N, 8.30%.
2.2.2.12. 1-(4-Fluoronaphthalen-1-yl)-3-[4-(4-ﬂuorophenyl)-3,6-
dihydropyridin-1(2H)-yl] propan-1-ol (23). Yield: 82%, mp 162-
163 C. 1H NMR (400 MHz. DMSO-d6) d: 8.20 (dd, 1H, J ¼ 7.0 Hz,
2.5 Hz), 8.07 (d, 1H, J ¼ 8.2 Hz), 7.70 (dd, 1H, J ¼ 8.0 Hz, 5.6 Hz),
7.54e7.61 (m, 2H), 7.35e7.40 (m, 2H), 7.18 (dd, 1H, J ¼ 10.2 Hz,
8.1 Hz), 7.00e7.08 (m, 2H), 6.00e6.05 (m, 1H), 5.74 (br s, 1H), 3.47
(d, 1H, J ¼ 11.3 Hz), 3.41 (d, 1H, J ¼ 11.2 Hz), 2.84e3.12 (m, 4H), 2.73
(br s, 2H), 2.14e2.20 (m, 2H) ppm. 13C NMR (DMSO-d6, 100 MHz) d:
160.99; 159.06; 139.11 (d, J ¼ 4.2 Hz); 137.42 (d, J ¼ 3.2 Hz); 133.87;
131.99 (d, J ¼ 4.3 Hz); 127.79; 127.31 (2C, d, J ¼ 8.0 Hz); 127.02 (d,
J ¼ 1.6 Hz); 124.55 (d, J ¼ 2.6 Hz); 123.77 (d, J ¼ 1.0 Hz); 123.65 (d,
J ¼ 8.8 Hz); 122.91 (d, J ¼ 1.4 Hz); 121.30 (d, J ¼ 5.8 Hz); 115.92 (2C,
d, J ¼ 21.2 Hz); 109.82 (d, J ¼ 19.2 Hz); 68.80; 55.72; 53.85; 50.82;
36.75; 28.43 ppm. Anal. Calcd for C24H23NF2O: C, 75.99%; H, 6.07%;
N, 3.69%; Found: C, 75.65%; H, 6.45%; N, 3.50%.
2.2.2.13. Hydrochloride of 1-(4-ﬂuorophenyl)-3-[4-(4-nitro-2-
triﬂuoromethylphenyl) piperazin-1-yl]propan-1-ol (24). Yield: 20%,
mp 163-165 C, 1H NMR (400 MHz, DMSO-d6) d: 11.20 (br s, 1H),
8.47 (d, 1H, J ¼ 8.8 Hz), 8.42 (s, 1H), 7.64 (d, 1H, J ¼ 9.0 Hz), 7.42 (dd,
2H, J ¼ 8.0 Hz, 6.6 Hz), 7.18 (t, 2H, J ¼ 8.1 Hz), 5.65 (s, 1H), 4.69 (s,
1H), 3.60 (br s, 2H), 3.35e3.44 (m, 4H), 3.15e3.20 (m, 4H), 2.09 (bs,
2H) ppm. 13C NMR (DMSO-d6, 100 MHz) d: 162.08; 159.50; 154.72;
150.40; 142.21; 140.75 (d, J ¼ 2.3 Hz); 128.22 (2C); 127.09 (d,
J¼ 8.1 Hz); 123.74; 123.21 (d, J¼ 5.2 Hz); 114.35 (2C, d, J¼ 21.0 Hz);
66.47; 54.20; 52.04 (2C); 50.07 (2C); 31.83 ppm. Anal. Calcd for
C20H21N3F4O3 .HCl.H2O: C, 49.85%; H, 5.02%; N, 8.72%; Found: C,
49.50%; H, 4.76%; N, 8.63%.
2.2.2.14. Hydrochloride of 1-(4-ﬂuorophenyl)-3-[1-(4-nitro-2-
triﬂuoromethylphenyl) piperidin-4-yl)amino]propan-1-ol (25).Yield: 11%, mp 185-187 C, 1H NMR (400 MHz, DMSO-d6) d: 8.37 (br
s, 2H), 7.50 (d, 1H, J ¼ 8.0 Hz), 7.36 (br s, 2H), 7.13 (t, 2H, J ¼ 8.1 Hz),
5.61 (s, 1H); 4.69 (t, 1H, J ¼ 9.0 Hz), 3.20e3.30 (m, 2H), 2.95 (t, 2H,
J ¼ 12.1 Hz), 2.63e2.64 (m, 2H), 2.58 (br s, 1H), 1.90 (d, 2H,
J ¼ 11.0 Hz), 1.70 (br s, 2H), 1.38 (br s, 2H) ppm. 13C NMR (DMSO-d6,
100 MHz) d: 163.06; 160.66; 157.70; 143.19 (d, J ¼ 2.7 Hz); 141.73;
129.21; 128.34 (2C, d, J ¼ 8.0 Hz); 124.98 (q, J ¼ 6.0 Hz); 123.88;
122.82; 115.49 (2C, d, J ¼ 21.1 Hz); 71.59; 54.24; 52.08 (2C); 44.00;
35.62; 32.34 (2C) ppm. Anal. Calcd for C21H23N3F4O3 .HCl: C,
52.51%; H, 5.03%; N, 8.80%; Found: C, 52.13%; H, 4.91%; N, 8.49%.
2 .2 .2 .15 . 1-(4-ﬂuorophenyl ) -3- [4-(4-ﬂuorophenyl ) -3 ,6-
dihydropyridin-1(2H)-yl]propan-1-ol (26). Yield: 12%, mp 199-
201 C. 1H NMR (400 MHz, DMSO-d6) d: 7.46 (dd, 2H, J ¼ 7.7 Hz,
5.5 Hz), 7.37 (dd, 2H, J ¼ 7.9 Hz, 6.0 Hz), 7.14 (dd, 4H, J ¼ 12.6 Hz,
8.0 Hz), 6.12 (br s, 1H), 5.49 (br s, 1H), 4.66 (t, 1H, J¼6.3 Hz), 3.06 (br
s, 2H), 2.57e2.62 (m, 2H), 2.45 (br s, 4H),1.76e1.80 (m, 2H) ppm. 13C
NMR (DMSO-d6, 100 MHz) d: 160.98; 159.80; 141.53; 139.87 (d,
J ¼ 3.0 Hz); 133.85; 128.40 (2C, d, J ¼ 8.0 Hz); 127.78; 127.25 (2C, d,
J ¼ 8.0 Hz); 115.80 (2C, d, J ¼ 21.2 Hz); 115.29 (2C, d, J ¼ 21.0 Hz);
71.89; 55.87; 53.57; 50.62; 36.96; 28.34 ppm. Anal. Calcd for
C20H21NF2O.¼H2O: C, 71.88%; H, 6.43%; N, 4.19%; Found: C, 72.06%;
H, 6.33%; N, 4.03%.
2.3. Separation and testing of the APD enantiomers
The separation of enantiomers involved two steps: analytical
scale chiral chromatography and preparative scale chiral chroma-
tography. For analytical chromatography, an isocratic method was
developed on the ACQUITY UltraPerformance Convergence Chro-
matography System™ (UPC2)® from Waters. The fast screening
strategy was performed testing organic modiﬁers (MeOH, iso-
propanol (i-Pr), and diethylamine (DEA), all HPLC grade in the CO2
mobile phase and 5 chiral columns (Chiralpak IA, OD, AD, OJ and IC,
100  4.6 mm i.d. column, Chiral Technologies, Daicel Group). The
mobile phase composition was controlled by four pumps. The
pump head used for the carbon dioxide was cooled. The mobile
phase conditions were optimized to obtain efﬁcient elution times
and separation factors. The analytical ﬂow ratewas 3.5mL/min. The
outlet pressure was 130 bar and the columns were maintained at
40 C. The PDA detector was set at 342 nm. Injection volume was
10 mL. The best conditions were obtained using Chiralpak IC column
with 20% of i-Pr þ 0.1% DEA as an additive in the CO2 mobile phase.
The retention times for each of the enantiomerswere rt1¼4.65min
and rt2 ¼ 5.60 min.
For the enantiomeric separation of compound 25, supercritical
preparative scale chromatography was performed on a Puriﬁcation
Prep 80 system (Waters). Chiral separation was run on Chiralpak IC
column, 5 mm (20  250) mm column (Chiral Technologies, Daicel
Group) elutedwith amixture of CO2 and 15% of i-Prþ 0.1% DEA. The
working ﬂow was 80 mL/min. The automated back pressure valve
was regulated to 130 bar and the oven temperature was 40 C. The
UV detection was performed at 342 nm. The injection volume was
1mL of an upstream ﬁltered concentrated solution of 5 g/L of i-Pr in
stacked mode. All fractions containing enantiomers 1 and 2 were
collected in the same bottles A and B, respectively. Finally, each
enantiomer and racemic mixture of compound 25 were evaluated
against P. falciparum F32 Tanzania strain (chloroquine sensitive)
according to Bouquet et al. (2012).
2.4. In vitro antiplasmodial activity (FCR-3 strain)
The multidrug resistant FCR-3 strain of P. falciparum was
cultured at 37 C in a pure gas mixture of 5% O2, 5% CO2, and 90% N2
environment in RPMI 1640 medium supplemented with 25 mM
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inactivated human serum, as previously described (Trager and
Jensen, 1976). Compounds were dissolved in DMSO and tested
with ﬁnal concentrations ranging between 0.1 and 200 mM. The
ﬁnal DMSO concentration was never greater than 0.1%. In vitro
antimalarial activity was measured using the [3H]-hypoxanthine
(MP Biomedicals, USA) incorporation assay (Desjardins et al., 1979)
with some modiﬁcations. All experiments were performed in
triplicate. Results were expressed as the concentration resulting in
50% inhibition (IC50) which was calculated by linear interpolation
(Huber and Koella, 1993) as follow:
LogðIC50Þ ¼ LogðX1Þ þ
ð50 Y1Þ
ðY2 Y1Þ ½LogðX2Þ  LogðX1Þ
Where:
X1: concentration of the drug that gives a % inhibition of the
parasitemia Y1>50%
X2: concentration of the drug that gives a % inhibition of the
parasitemia Y2<50%
% Inhibition of the incorporation of labeled hypoxanthine¼ 100-
(P/T*100)
P: counts per minute for every concentration
T: negative control (red blood cells without drug)2.5. In vivo antimalarial activity
Studies were conducted according to the French and Colombian
guidelines on laboratory animal use and care (N 2001-464 and N
008430, respectively). The classical 4-day suppressive test was
carried out as follows (Peters, 1970). Swiss male mice weighing
20 ± 2 g, were infected with 107 P. berghei ANKA parasitized cells
(day 0). Two hours after infection and at the same time during 4
consecutive days, batches of three to ﬁve mice were orally treated
at a dose of 50 mg/kg/day (drugs were dissolved in vehicle,
water:DMSO). A control group received the vehicle while a refer-
ence group was orally administered chloroquine diphosphate at
3 mg/kg/day. Survival of the mice was checked daily and the per-
centage of parasitized erythrocytes was determined on day 4 by
Giemsa-stained thin blood smears made from peripheral blood.
2.6. Cytotoxicity assay
VERO cells (African Green Monkey kidney epithelial cells) were
seeded (5 105 cells/mL, 100mL/well) in a 96-well ﬂat-bottom plate
at 37 C and with 5% CO2 in phenol red free RPMI 1640 (Sigma)
supplemented with 10% heat-inactivated fetal bovine serum.
Compounds were added at varying concentrations and the cells
were cultured for 48 h. The effect was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
viability assay (Mosmann, 1983). Four hours after the addition of
MTT, 100 mL of lysis buffer (50% i-Pr, 30% water, 20% (w/v) SDS) was
added and the cells were incubated at room temperature for 15min
under agitation. Finally, optical density was read at 590 nm with a
96-well scanner (Bio-Rad). All experiments were performed in
triplicate. The GI50 determined by linear regression analysis was
deﬁned as the concentration of test sample resulting in 50% inhi-
bition of cell proliferation compared to controls.
2.7. In silico physicochemical properties calculation
Virtual Computational Chemistry Laboratory (Tetko et al., 2005)
(http://www.vcclab.org/) and Molinspiration online propertycalculation toolkit (http://www.molinspiration.com/cgi-bin/
properties) were used to calculate Topological Polar Surface Area
(TPSA) (Ertl et al., 2000), ALOGPs2.1, number of rotatable bonds and
violations of Lipinski's rule of ﬁve (Lipinski et al., 1997). In addition,
human intestinal absorption (%ABS) was calculated using the
following approach of Zhao et al. (2002):
%ABS ¼ 109 eð0:345  TPSAÞ2.8. Genotoxicity assay
The SOS/umu test was used to determine the DNA-damaging
effect and was carried out according to the method of Oda et al.
(1985) and Reifferscheid et al. (1991) with some modiﬁcations.
The test strain Salmonella typhimurium TA1535/pSK1002 (German
Collection for microorganisms and cell cultures (DSMZ) was
thawed from stock (80 C; in TGA medium containing 10% DMSO
as cryoprotective agent) and 0.5 mL of bacteria was resuspended in
100 mL TGA medium supplemented with ampicillin (50 mg/mL).
The test strain suspension was incubated overnight at 37 C with
slight orbital shaking (155 rpm) until an optical density was
reached (OD600 between 0.5 and 1.5). Then, the overnight culture
was diluted with fresh TGA medium (not supplemented with
ampicillin) and incubated for 2 h at 37 C, 155 rpm, in order to
obtain a log-phase bacterial growth culture (OD600 between 0.15
and 0.4). The test was performed in the absence and presence of an
external metabolic activation system (10% of rat S9 mix, prepared
from S9 SD rat liver Aroclor KCl frozen, Trinova, Germany), in order
to also determine the possible genotoxic effects of any metabolite.
In each test performed negative and positive controls were
included with DMSO used as the negative control and 4-
nitroquinoline-N-oxide (4-NQO) (Sigma-Aldrich, China) and 2-
aminoanthracene (2-AA) (Sigma-Aldrich, Germany) used as posi-
tive controls in the absence and presence of S9 mix, respectively.
Test procedure was as follows: ﬁrst, each compound tested was
dissolved in DMSO at 40 mg/mL (for a ﬁnal assay concentration of
1 mg/mL) and 11 serial½ dilutions were prepared in a 96-well plate
(plate A; ﬁnal volume in each well was 10 mL). In case where cell
survival was <80% in the lowest concentration tested, new 11 serial
½ dilutions at lower concentrations were prepared. The highest
concentrations of DMSO used for the positive controls were 100 mg/
mL for 4-NQO (ﬁnal concentration: 2.5 mg/mL) and 0.5mg/mL for 2-
AA (ﬁnal concentration: 0.0125 mg/mL). Then, 70 mL of water was
added to each well and evaluated in order to detect any precipi-
tation of the compounds. In two other 96-well plates (plates B; one
with S9 and the other without S9), 10 mL S9 mix or 10 mL PBS,
respectively were added and afterwards, 25 mL of each concentra-
tion of compound previously prepared. Finally, 90 mL of exponen-
tially growing bacteriawas added to eachwell and both plates were
incubated for 4 h by shaking (500 rpm) at 37 C. After the incu-
bation period, the OD600 was measured in order to evaluate toxicity
on S. typhimurium TA1535/pSK1002.
Toxicity was calculated as follows:
Survival percentage ¼

A600nm for each concentration tested
Media A600nm for negative control

 100%
Afterwards, for the determination of b-galactosidase activity, in
two new 96-well plates (plates C) 150 mL ONPG solution (2-
nitrophenyl-b-D-galactopyranoside, Sigma-Aldrich, Switzerland)
(0.9 mg/mL in B-buffer prepared according to Reifferscheid et al.
(1991) was added to each well and 30 mL of the content of each
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incubated 30 min by shaking (500 rpm) at 28 C avoiding direct
light exposure. After the incubation period, the reaction was
stopped by adding 120 mL of Na2CO3 (1M). Absorbance at 420 nm
was then measured immediately, and b-galactosidase activity
(relative units; RU) was calculated as follows:
b galactosidase enzymatic units
¼ A420nm for each concentration tested
A600nm for each concentration tested
And ﬁnally, the induction factor (IF) was calculated as follows:
IF ¼ b galactosidase RU for each concentration tested
Average b galactosidase RU for negative control
Where:
Average b galactosidase RU for negative control
¼ Average A420nm for negative control
Average A600nm for negative control
In the same way, b-galactosidase relative units were calculated for
both positive controls and the test was only considered valid if the
positive controls reached an induction factor 2 under the given
test conditions.
Thus, a compound was considered genotoxic when in any of the
conditions studied (with or without metabolic activation) the IF of
the umu operon was 2 at non-cytotoxic concentrations (bacteria
survival percentage 80%). Any well where compound precipita-
tion was observed was discarded from analysis.2.9. In vitro antiplasmodial activity (D6 and C235 strains)
A chloroquine sensitive (D6, obtained from Walter Reed Army
Institute of Research) and multidrug resistant (C235, obtained from
Walter Reed Army Institute of Research) strain of P. falciparumwere
continuously cultured following modiﬁcations to the original
Trager and Jensen method (1976). Each strainwas maintained at 5%
hematocrit using human Aþ erythrocytes and incubated at 37 C in
a pure gas mixture of 5% O2, 5% CO2, and 90% N2. Culture media
included RPMI 1640 with L-glutamine and supplemented with
25 mM HEPES, 11 mM glucose, 29 mM hypoxanthine, 29 mM so-
dium bicarbonate, and 10% human Aþ heat-inactivated human
plasma. Drug susceptibility was determined using theMalaria SYBR
Green-I Fluorescence (MSF) assay (Johnson et al., 2007). Com-
pounds were dissolved in DMSO at a concentration of 10 mM and
were subsequently transferred to assay plates (Nunc MicroWell
384-well optical bottom) in duplicate using an ECHO 555 liquid
handler. Final compound concentrations ranged between 0.03 and
24.90 mM (0.25% DMSO) to establish IC50 values. Controls of 0.25%
DMSO, no DMSO, and 110 mM amodiaquine were used to assess the
quality of each plate. The D6 and C235 strains were sorbitol syn-
chronized to the ring stage, added to the plate at an initial 0.3%
parasitemia level and 2% hematocrit, and incubated for 72 h. The
parasites were then lysed with 10 mM EDTA, 100 mM Tris-HCl (pH
7.5), 0.16% (w/v) saponin, and 1.6% (v/v) Triton X-100, mixed with
SYBR Green-1 (1:10,000 dilution) and incubated in the dark for
24 h. Fluorescence was read using a Synergy H4 Hybrid Plate
Reader (BioTek) (Exc: 485 nm, Em: 535 nm) with concentration
response curves generated using the sigmoidal dose response
variable slope curve ﬁt on GraphPad Prism v5.0.2.10. Antiplasmodial activity and genotoxicity study for chemical
intermediates
The commercially available intermediate 4-(4-ﬂuorophenyl)-
1,2,3,6-tetrahydropyridine (AM01) and the synthesized interme-
diate 4-(4-nitro-2-triﬂuoromethylphenyl)aminopiperidine (AM02)
were tested against P. falciparum FCR-3 multidrug resistant strain
using the methodology followed to evaluate ﬁnal compounds
(14e26). Genotoxicity test SOS/umu was performed on AM01 and
AM02 using the protocol followed to evaluate ﬁnal compounds (22,
23, 24, and 25). MetaSite software 3.0.4 (Molecular Discovery Ltd.)
was used to predict human liver metabolism (site of metabolism)
and potential metabolites using the P450 liver model that involves
the three major liver isoforms (CYP3A4, CYP2C9, and CYP2D6).
Although MetaSite does not have mouse CPY models, it is well
known that these human isoforms havemouse homologs (Cui et al.,
2012). To perform the predictions, MetaSite only used 3D structures
of potential substrates as described by Cruciani et al. (2005).
Structures were submitted to MetaSite as simpliﬁed molecular
input line entry system notation (SMILES), the reactivity correction
option and a minimal mass threshold of 50 Da for predicted me-
tabolites were used. The site of metabolism is shown as soft spots
graphic with a report as a histogram bar chart showing the prob-
ability of metabolism for any of the atoms.2.11. Plasmepsin assay
PM2 (200 nM) was preincubated for 5 min, 37 C in 0.1 M so-
dium formate, pH 4.4. Compounds dissolved in 100% DMSO were
added to the enzyme for a ﬁnal concentration of 5 mM (ﬁnal DMSO
concentration of 2%) and incubated with enzyme for 5 min. The
preincubation time allows for complete conversion of the zymogen
to active mature form of the enzyme. The reaction was initiated by
the addition of 20 mM RS6 peptide (K-P-I-E-F-Nph-R-L). The sub-
strate cleavage reaction was monitored by the decrease in the
average absorbance from 284 to 324 nm on a Cary 50 Bio Varian
spectrophotometer equipped with an 18-cell multitransport sys-
tem. Reactions with inhibitor were compared to control reactions
containing 2% DMSO only.2.12. b-hematin inhibition assay
An in vitro assay developed by Sandlin et al. was used to test for
b-hematin, abiological hemozoin, inhibition activity (Sandlin et al.,
2011). Test compounds were screened between 0.44 and 110 mM
with a ﬁnal DMSO concentration of 0.25% in a clear 384-well ﬂat
bottom microtiter plate (Corning). Positive controls of 80 mM
amodiaquine and negative controls of 0.25% DMSO were used to
evaluate the validity of the assay. Following the addition of each
compound, 20 mL of water and Nonidet P-40 detergent (30.5 mM
ﬁnal concentration) were added to each well to mediate crystal
formation. A 25 mM hemin chloride stock was prepared in DMSO
andwas passed through a 0.22 mmPVDFmembrane ﬁlter. From this
stock solution, a 228-mM hematin suspension was prepared in 2 M
acetate buffer (pH 4.8) and added to the plate for a ﬁnal hematin
concentration of 100 mM. After a 6 h shaking incubation at 37 C,
pyridine was added to the plate (5% v/v ﬁnal concentration) and
was shaken an additional hour. The absorbance of the pyridine-
ferrochrome complex was measured at 405 nm using a Synergy
H4 Hybrid Plate Reader (BioTek). Dose response curves were
generated from the maximum absorbance values using a nonlinear
regression of sigmoidal dose response variable slope curve ﬁt on
GraphPad Prism v5.0.
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The compound's ability to affect the hemozoin formation
pathway as a drug target was validated with the heme speciation
assay (Combrinck et al., 2015). A D6 culture was sorbitol synchro-
nized to the early ring stage and diluted to 5% parasitemia and 2%
hematocrit. This culture was distributed in 2 mL aliquots to a 24-
well ﬂat bottom cell culture plate containing the test compound.
A control sample of no drug was included alongside ﬁve varying
concentrations, each in quadruplicate, based on the IC50 values
previously determined by theMSF assay. The plates were incubated
at 37 C, 5% O2, 5% CO2, and 90% N2 for 32 h to allow for the parasite
to reach the trophozoite stage. The mature parasites were then
isolated from the erythrocytes through selective lysis with saponin
(0.05% ﬁnal concentration) and washed and resuspended in PBS. A
10 mL aliquot was removed from each sample for cell counting with
the Countess II FL automated cell counter. The trophozoite pellet in
PBS was fractionated into the three heme species: P. falciparum
hemoglobin, free intracellular heme, and hemozoin as described by
Combrinck et al. (2015). The maximum absorbance of the Fe (III)
heme-pyridine complex that results from each of the fractionation
steps was recorded at 405 nm in order to calculate the ratios of
heme species in each sample.
2.14. Heme binding studies
Spectrophotometric titrations were conducted to further un-
derstand the interaction of each compound with the m-oxo heme
dimer in vitro. First, each compound was dissolved in 40% aqueous
DMSO and 0.02 M HEPES (pH 7.4) and serial diluted into a clear 96-
well microtiter plate in triplicate. A hemin solution in the same
solvent system was added to the plate to a ﬁnal concentration of
5 mM. The platewas incubated for 1 h in the dark prior tomeasuring
the absorbance at 400 nm using a Synergy H4 Hybrid Plate Reader
(BioTek). Titrations were conducted without the heme addition to
account for any absorbance from the compound itself at 400 nm
and these values were subtracted from the ﬁnal results. Absorbance
values were plotted using a nonlinear least squares ﬁt with CurveFit
v1.00 to determine the equilibrium association constant.
2.15. Three-dimensional pharmacophore model for new APD
The LigandScout software (Wolber and Langer, 2005) 4.09.2
(InteLigand GmbH Ltd.) was used to build and describe the phar-
macophore models. Models were obtained using the ligand-based
pharmacophore design that is implemented in the espresso mod-
ule. For the APD model, the most active compounds were used as a
training set (22, 23, 24, and 25; FCR-3 IC50  0.5 mM), which
included both possible enantiomers (R and S conﬁgurations) for
each compound. For the classical arylamino alcohols (CAA), a
consensus model was generated using the four molecules (quinine,
meﬂoquine, lumefantrine, and halofantrine) and respective
stereoisomers.
All molecules used in the pharmacophore study were drawn
using ChemDraw Ultra software 7.0 (CambridgeSoft Ltd.) with
stereoisomerism manually checked. Then, structures were sub-
mitted to LigandScout as SMILES. For each molecule, a three-
dimensional (3D) multiconformational calculation was performed
using the Icon conformer generation tool in LigandScout. The Best
Setting option was used to generate the conformations (maximum
number of conformations ¼ 400, timeout ¼ 600, RMS
threshold ¼ 0.8, energy window ¼ 20, maximum pool size ¼ 4000,
and maximum fragment build time ¼ 30). To generate models, the
Merge Feature Pharmacophore option was used to take all the
features into account and assemble them into one pharmacophoremodel (consensus model). The scoring function used to rank the
models was Pharmacophore-Fit and Atom Overlap. The maximum
number of pharmacophore models generated was ten. The model
with the highest score was manually checked and considered as
valid, since the model exhibited the molecules properly aligned.
Pharmacophore representation including hydrophobic features
(HPF), hydrogen bond donor features (HBDF), hydrogen bond
acceptor features (HBAF), positive ionizable features (PIF), and ar-
omatic ring features (ARF) were projected on molecules. For com-
parison of the ﬁnal pharmacophore models (APD and CAA), a
consensus model was constructed for APD. The R and S models
were aligned using the alignment module in LigandScout. Both
pharmacophores were merged and the overlapping features were
interpolated. Finally, the new pharmacophore model for APD was
aligned with the consensus pharmacophore model for CAA where
only common features in both models were calculated and
extracted.
3. Results and discussion
3.1. Separation and testing of the APD enantiomers
Chiral separation of compound 25 was made using ultra per-
formance convergence chromatography with a Chiralpack IC col-
umn (Supplementary Data Fig. 1). There were no signiﬁcant
potency differences between the compound 25 enantiomers and
racemic mixture against P. falciparum F32 Tanzania, chloroquine
sensitive strain (F32 IC50 z 0.50 mM). The biological data for the
two enantiomers of the compound 25 is shown in the
Supplementary Data Table 1. Based on these results, we continued
with synthesis and testing of the APD as racemates.
3.2. In vitro antiplasmodial activity (FCR-3 strain)
The activity of thirteen newly synthesized hydroxyl analogues
(14e26) was determined against FCR-3 multidrug resistant strain
(resistant to chloroquine, cycloguanil, and pyrimethamine)
(Table 1). Chloroquine was used as a reference drug in all experi-
ments for comparison (FCR-3 IC50¼ 0.13 mM). Compounds 17,18, 21,
22, 23, 24, 25, and 26 all resulted in submicromolar activity (FCR-3
IC50 < 1 mM) with four of these below 0.5 mM (22, 23, 24 and 25).
Overall, incorporation of a single ﬂuorine atom in the Ar (hy-
drophobic) region provided potency across the different benzo[b]
thiophene, naphthalene, and benzene derivatives (Table 1, com-
pounds 14e18 and 21e26, IC50  2.23 mM). Compounds with a
single ﬂuorine atom in the Ar region (23 and 26) exhibited 35-fold
and 9-fold increase in potency, respectively, compared to 19 and 20
(23 vs 19 and 26 vs 20), thereby conﬁrming our previous obser-
vations of its requirement for antiplasmodial activity (Perez-Silanes
et al., 2009; Mendoza et al., 2011). A good example of this obser-
vation is the comparison the IC50 values of previous non-
ﬂuorinated analogues (* compounds) with new APD (see
Supplementary Data Table 2, 14 vs *7 and 15 vs *8). Exploration of
the Ar region showed that 4-ﬂuoro-1-naphthyl derivatives are 5-
fold more active than 5-ﬂuorobenzo[b]thiophenyl analogues (18
vs 22) and 1- to 3-fold more active than 4 ﬂuoro-1-phenyl ana-
logues (23 vs 26 and 22 vs 25) (Table 1). Interestingly, a particular
study on ß-amino alcohols and their corresponding hydrophobic
regionmust be highlighted due to its structural similarity with APD.
Tacon et al. (2012) reported loss of antiplasmodial activity in de-
rivatives compared with their corresponding totarol analogues.
This loss of activity has involved the structural replacement of the
totarol scaffold by simpler aromatic systems, common in APD, such
as phenyl and naphthyl. As a result the compounds exhibited IC50
values ranging between 5 and 100 mM (D10 strain, P. falciparum).
Table 1
In vitro antimalarial activity against multidrug-resistant strain (FCR-3) of P. falciparum and VERO cytotoxicity of compounds 14e26.
Compound Ar Amine R1 R2 FCR-3 IC50 (mM)a CC50 (mM)b SIc
14 CF3 NO2 1.32 ± 0.20 >200 >150
15 NO2 CF3 2.23 ± 0.20 >150 >50
16 H CF3 1.68 ± 0.60 >250 >100
17 CF3 NO2 0.75 ± 0.02 13.3 18
18 CF3 NO2 0.70 ± 0.10 6.3 9.00
19 H F 14.03 ± 3.50 24.60 1.75
20 H F 5.60 ± 2.30 >350 >50
21 H CF3 0.93 ± 0.70 >100 >100
22 CF3 NO2 0.15 ± 0.01 5.5 37
23 H F 0.40 ± 0.01 49.5 124
24 CF3 NO2 0.36 ± 0.14 88 244
25 CF3 NO2 0.48 ± 0.04 30.20 63
26 H F 0.66 ± 0.01 >100 >150
CQd 0.13 >50
Doxorubicin nt 6.4 nt
a FCR-3 IC50 values are the growth inhibition of 50% of P. falciparum parasites.
b CC50 values are the inhibition of 50% of VERO cells survival.
c SI (selectivity index) ¼ CC50 (cytotoxicity)/IC50 (FCR-3).
d CQ: chloroquine. nt: not tested.
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atom in the hydrophobic portion.
It is noteworthy that electron-withdrawing groups at the para
position on the phenyl ring such as -CF3, -NO2, and -F were well
tolerated and resulted in highly active compounds (21, 22, 23, 24,
25, and 26). By varying the position of the substituents from para to
ortho (nitro group as R2 and R1 as triﬂuoromethyl group) the ac-
tivity decreases (14 vs 15). This ﬁnding reinforced our preliminary
observations that indicate the necessity of a hydrophobic group at
the ortho position to improve activity (Mendoza et al., 2011).
Additionally, when the triﬂuoromethyl group is substituted at the
para position and the nitro group is removed, the activity remains
almost unchanged (14 IC50 ¼ 1.32 mM vs 16 IC50 ¼ 1.68 mM).
The central amine also inﬂuences the activity as seen with
aminopiperidine analogues that are more active than piperazine
analogues (14 vs 18 and 21 vs 22 vs 23). The same trend is observed
when compound 22 is compared with an analogue previously
published by our group where only piperazine was replaced
(Mendoza et al., 2011). In relation to the exploration of arylamines,
this ﬁnding is in agreement with the results reported byMolyneauxet al. (2005) that show unsubstituted amines (free NH) have sig-
niﬁcant antiplasmodial activity in resistant strains compared to
their substituted analogues. One feasible explanation is that
unsubstituted nitrogen (NH) may interact easily with possible tar-
gets, as there is a greater hydrogen bond capacity.
3.3. Cytotoxicity assay
The cytotoxicity of the thirteen newly synthesized hydroxyl
analogues (14e26) was determined against VERO cells using the
MTT-assay (Mosmann,1983) (Table 1). The cytotoxic assays showed
that analogues with aminopiperidine as the central amine aremore
cytotoxic than piperazine and tetrahydropyridine (14 vs 18, 24 vs
25, and 22 vs 23 vs 26, respectively). Additionally, Tacon et al.
(2012) and our group have also reported low cytotoxicity in ß-
and g-amino alcohols with aryl-piperazinyl groups. In general, with
the exception of compound 19, all tetrahydropyridine and pipera-
zine derivatives showed negligible cytotoxicity in VERO cells. In this
context, an important criterion was the degree of selectivity of the
APD that was expressed as selectivity index (SI) (Table 1), where a
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cells. The most active compounds (22, 23, 24, and 25) showed
moderate to high degree of selectivity index (37  SI  244).
3.4. In silico physicochemical properties (ADME proﬁle)
A computational study was performed for the prediction of an
ADME proﬁle of all hydroxyl analogues (Table 2). Topological polar
surface area (TPSA) is a good descriptor of drug absorbance in the
intestines, Caco-2 monolayer penetration, and blood-brain barrier
crossing (Ertl et al., 2000). TPSA was used to calculate the per-
centage of human intestinal absorption (%ABS) according to the
equation: %ABS ¼ 109e0.345  TPSA, as shown by Zhao et al.
(2002). In addition, Lipinski's rule of ﬁve (Lipinski et al., 1997)
and the number of rotatable bonds (n-ROTB) (Veber et al., 2002)
were also calculated in order to evaluate their druglikeness. From
these parameters, all compounds exhibited a %ABS ranging be-
tween 80 and 100%. Only compounds 19 and 23 violated one Lip-
inski's parameter, 23 being at the limit (ALOGPs¼ 5). Therefore, the
oral bioavailability of hydroxyl analogues could be considered
interesting as agents for antimalarial therapy.
3.5. Genotoxicity assay
Studies to analyze the DNA-damaging effect or genotoxicity of
the most active compounds were performed. The nitro substituent
often causes safety concerns due to its well-documentedmutagenic
and carcinogenic potential (Purohit and Basu, 2000). Thus, the SOS/
umu test was included as a preliminary genotoxicity screening
assay because of the high degree of agreement between the SOS/
umu test and the standardized Ames test (OECD guideline 471)
(Reifferscheid and Heil, 1996). Compounds 22, 23, 24, and 25 were
not considered genotoxic since the induction factor (IF) was always
lower than 2 at non-cytotoxic concentrations with or without S9
fraction (Supplementary Data Table 3). It should be noted, however,
that in the ﬁrst screening assay all the concentrations of 22 were
cytotoxic (<80% survival) when tested in absence of metabolic
activation and thus further testing at non-cytotoxic concentrations
was needed to understand its genotoxic effects. A second screening
test was performed at lower concentrations in order to have a
larger range of non-cytotoxic concentrations (Supplementary Data
Table 4). Again, none of the compounds showed an IF higher than
two. Additionally, if a high degree of agreement between the SOS/Table 2
In silico physicochemical properties of tested compounds (ADME proﬁle).
ID %ABS TPSA (Ǻ2) n-ROTB Molecular weight ALO
rule 10 <500 <5
14 84 72.5 7 483.49 4.47
15 84 72.5 7 483.50 4.49
16 100 26.7 6 438.49 4.83
17 84 72.5 7 497.51 4.81
18 81 81.3 8 497.51 4.31
19 100 23.5 5 361.46 5.27
20 100 23.5 6 379.74 4.41
21 100 26.7 6 432.46 4.77
22 81 81.3 8 491.47 4.39
23 100 23.5 5 379.45 5.00
24 84 72.5 7 427.44 3.75
25 81 81.3 8 441.47 3.47
26 100 23.5 5 329.39 4.12
CQ 99 28.2 8 319.90 5.28
%ABS: human intestinal absorption, calculated by: %ABS ¼ 109-(0.345xTPSA); TPSA: to
logarithm of compound partition coefﬁcient between n-octanol and water; n-OHNH: n
chloroquine; molecular weight expressed as Dalton.umu test and Ames test was found (Reifferscheid and Heil, 1996),
the SOS/umu test was used for screening purposes and selecting the
best candidates. For regulatory purposes, negative results should be
further evaluated with the standardized Ames test.
3.6. In vivo antimalarial activity
Along with the extensive SAR and toxicological studies, in vivo
antimalarial activity in the P. berghei mouse model was evaluated
following oral administration. The criteria to select compounds was
based on FCR-3 IC50  0.5 mM, SI > 35, appropriate in silico
bioavailability, and a negative genotoxicity test. Thus, parasitemia
reduction and mean survival days (MSD) for chloroquine and
promising APD compounds (22, 23, 24, and 25) were evaluated at a
unique oral dose (50 mg/kg  4 days) (Table 3). Compound 22
displayed excellent parasitemia reduction (98± 1%), and complete
cure with all treated mice surviving through the entire 21-day
period with no signs of toxicity (MSD > 35). Compounds 23 and
25 showed parasitemia reduction of 73 ± 16% (MSD ¼ 9) and
76 ± 30% (MSD¼ 5), respectively. Despite its antiplasmodial activity
(FCR-3 IC50 ¼ 0.36 mM), compound 24 was inferior in terms of
in vivo parasitemia reduction (17 ± 8%; MSD ¼ 8). Almost all pre-
vious studies on g-to ß-amino alcohol have not carried out in vivo
efﬁcacy studies. Apart from our group (Perez-Silanes et al., 2009;
Mendoza et al., 2011), only Bahamontes-Rosa et al. (2009) and
Guy et al. (Lowes et al., 2012), have explored the in vivo efﬁcacy of
ß-amino alcohol with unsuccessful results (parasitemia
reduction  60%). Thus, compounds 22, 23, and 25 appear as
interesting compounds for future antimalarial programs, due to the
agreement between in vitro and in vivo studies for these
compounds.
3.7. In vitro antiplasmodial activity (D6 and C235 strains)
As previously mentioned, two important factors in developing
APD as effective antimalarials are generating compounds with
remarkable potency against both chloroquine sensitive and multi-
drug resistant strains of P. falciparum. In order to evaluate and
validate the series quality (MMV, 2008), the IC50 values for the best
compounds were independently evaluated and validated in two
laboratories utilizing two different strains of P. falciparum. Only
three compounds with in vivo parasitemia reduction above 70%
were tested against the D6 chloroquine sensitive (but naturally lessGPs 2.1 n-OHNH Donors n-ON acceptors Lipinski's violations
<5 <10 1
1 6 0
1 6 0
1 3 0
1 6 0
2 6 0
1 2 1
1 2 0
1 3 0
2 6 0
1 2 1
1 6 0
2 6 0
1 2 0
1 3 1
pological polar surface area; n-ROTB: number of rotatable bonds; ALOGPs (LogP):
umber of hydrogen bond donors; n-ON: number of hydrogen bond acceptors; CQ:
Table 3
In vivo antimalarial efﬁcacy of selected compounds in P. berghei-infected mice.
Compound Ar Amine R1 R2 % Suppression of parasitemia (MSD)a
22 CF3 NO2 98 ± 1 (>35b)
23 H F 73 ± 16 (9)
24 CF3 NO2 17 ± 8 (8)
25 CF3 NO2 76 ± 30 (5)
CQc 87 ± 11 (16)
a MSD ¼ mean survival time (in days).
b Animals surviving beyond day 7 weremonitored by examination of blood ﬁlms every 7 days until day 35. At this time pooled blood was sub inoculated into cleanmice and
the absence of patent infection in these mice was veriﬁed until day 21 as evidence of curative activity.
c CQ: Chloroquine.
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(resistant to meﬂoquine, chloroquine, and pyrimethamine)
(Table 4).
Compounds 22 (D6 IC50 ¼ 0.11 mM, C235 IC50 ¼ 0.13 mM) and 23
(D6 IC50 ¼ 0.19 mM, C235 IC50 ¼ 0.28 mM) showed potent antima-
larial activity in both strains. In contrast, compound 25 was less
active against the multidrug resistant strain (D6 IC50 ¼ 0.49 mM,
C235 IC50 ¼ 1.05 mM). Notably, like chloroquine (see Table 1), these
APD compounds may act mechanistically different from meﬂo-
quine, a representative ß-amino alcohol, because of their high ac-
tivity against the meﬂoquine resistant strain, and therefore, would
not be affected by the samemechanism ofmeﬂoquine resistance. In
addition, the resistance indices (RI, Supplementary Data Table 7)
indicate that compounds 22 and 23were slightly more active in the
chloroquine sensitive strain. Compound 22 should be highlighted
due to its in vitro submicromolar values, with equal potency against
three different strains of P. falciparum (D6 IC50 ¼ 0.11 mM, C235Table 4
In vitro antimalarial activity against chloroquine sensitive strain (D6) and multidrug-resi
Compound Ar Amine R1 R2 An
D
22 CF3 NO2 0.
23 H F 0.
25 CF3 NO2 0.
CQ 0.IC50 ¼ 0.13 mM, and FCR-3 IC50 ¼ 0.15 mM).3.8. Antiplasmodial activity and genotoxicity study for chemical
intermediates
When exploring new compounds, it is crucial to determine the
lack of activity or genotoxicity of intermediates and potential me-
tabolites early in the drug discovery process. In the case of APD,
commercial or synthesized intermediates play a critical role for two
reasons: (1) TheMannich reaction, a key step in our synthetic route,
requires amines to obtain our ß-amino carbonyl intermediates
(1e13) and thus, are an important fragment of the ﬁnal compounds
(14e26); (2) As a possible product of human or mouse P450-
mediated oxidative metabolism of APD, these intermediates can
be potential metabolites. To explore the activity proﬁle, in-
termediates of the most active compounds (22, 23, and 25) were
tested against P. falciparum FCR-3 chloroquine resistant strainstant strain (C235) of P. falciparum.
timalarial activity IC50 (mM) b-hematin inhibition activity IC50 (mM)
6 C235
11 ± 0.01 0.13 ± 0.01 80.7 ± 1.7
19 ± 0.04 0.28 ± 0.05 Not active
49 ± 0.07 1.05 ± 0.02 Not active
014 ± 0.001 0.048 ± 0.004 48.7 ± 2.7
Table 5
In vitro antimalarial activity against P. falciparum multidrug-resistant strain (FCR-3)
of selected intermediates (potential metabolites).
Intermediate Chemical structure IC50 (mM)
FCR-3
AM01 8.2 ± 2.0
AM02 4.3 ± 0.9
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IC50 ¼ 4.3 mM, respectively) showed low antiplasmodial activity
compared to their ﬁnal products. To explore the probability of
obtaining the corresponding intermediates as potential metabo-
lites, an in silico approach using MetaSite software was performed.
This approach allowed for a simple, fast, and inexpensivemethod of
identifying the most probable site of metabolism (SoM) of the most
active compounds and therefore, predicts P450-derived metabo-
lites. As shown in Fig. 2, MetaSite predicted the P450 2C9-, P450
3A4-, and P450 2D6-catalyzed N-dealkylation of 22, 23, and 25 as
the most probable biotransformation pathway. Our predictions
indicated that N-dealkylation would occur principally on the side
chain a-carbon hydrogen(s) next to the amino aliphatic nitrogen for
22 and 25, and next to the tertiary amine for 23. In fact, our results
were reinforced by experimental and theoretical data found where
themetabolism of 4-aminopiperidine drugs werewell studied (Sun
and Scott, 2011). Genotoxicity proﬁles of intermediates (potential
metabolites) were performed using the SOS/umu test as a screening
test (Supplementary Data Table 5). Intermediates AM01 and AM02
were not considered genotoxic as the IF was always lower than 2 at
non-cytotoxic concentrations with or without S9 fraction. Thus, it
can be deduced that in vitro and in vivo antimalarial activity of
compounds 22, 23, and 25 is associated with the entire molecule
and not only to the amine scaffold intermediate. Additionally, the
viability to ﬁnd an intermediate as a product of CYPFig. 2. Plots of MetaSite predictions for sites of metabolism (SoM) for compounds 22, 23, an
liver isoforms (CYP3A4, CYP2C9, and CYP2D6). Red arrows indicate the most probable sit
bility.(For interpretation of the references to colour in this ﬁgure legend, the reader is refebiotransformation exists. Genotoxicity assay of potential metabo-
lites reinforce no genotoxic results observed with metabolic acti-
vation on APD. It should be noted that Metasite and SOS/umu
approaches were used for screening purposes and initial studies.
More in depth studies must be performed using standard assays
such as the Ames test and human or rat liver microsomal stability.3.9. Target exploration of plasmepsin II
Based on previous in silico studies performed by our group
(Mendoza et al., 2011), PM2 enzyme was proposed as a putative
target for APD. PM2, which is involved in the initial steps of he-
moglobin degradation, plays a critical role in the intraerythrocytic
cycle of the parasite. Consequently, in recent years PM2 has sparked
interest in the antimalarial community (Marvin and Daniel, 2012).
Docking studies showed a possible mode of union associated with
good afﬁnity values (Gibbs free energy). To conﬁrm our predictions,
eight compounds synthesized in this manuscript with anti-
plasmodial FCR-3 IC50 values ranging between 0.15 and 1.7 mMwere
tested against PM2. Compounds 14, 16, 17, 18, 22, 23, 24, and 25
(tested at 5 mM) showed no signiﬁcant inhibition of PM2 compared
to the control (Supplementary Data Table 6). Thus, PM2 was dis-
carded as a target for APD. Interestingly, our ﬁndings were better
understood when we compared our results with other hybrid
studies (computational and experimental approaches). Friedman
and Caﬂisch (2009) performed high-throughput docking simula-
tions using consensus-scoring methods to screen a database of
40,000 molecules resulting in 11 arylamino alcohols, halofantrine
and 10 structurally related to halofantrine and lumefantrine, that
were plasmepsin inhibitors (PM1, PM2, and PM3). Important facts
when analyzing and comparing our results include the following:
(1) Halofantrine shares the g-amino alcohol moiety with APD
(Fig. 1); (2) According to the proposed docking experiments, hal-
ofantrine may share the same theoretical binding mode as APD
(Friedman and Caﬂisch, 2009; Mendoza et al., 2011). This binding
mode includes one hydrogen bond between the oxygen of the
hydroxyl group and Asp214 and electrostatic interactions between
the nitrogen of the tertiary or secondary amine located near the
charged Asp34; (3) The unique major structural differences be-
tween APD and halofantrine (or its derivatives) are the aliphatic
chains of the four carbon length bond to the tertiary amine that ared 25. Predictions were performed using the P450 liver model that involves three major
e of metabolism. Soft spots intensity represents the potential metabolic sites proba-
rred to the web version of this article.)
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and Caﬂish (2009) for the 11 arylamino alcohols are considered
medium to low (2 mM IC50 100 mM), when comparedwith other
well-known plasmepsin inhibitors (IC50  0.01 mM) (Marvin and
Daniel, 2012). Based on these results, we reinforce the hypothesis
that the primarymechanism of action of arylamino alcohols such as
APD, halofantrine, lumefantrine, and meﬂoquine is not through
plasmepsin inhibition. Therefore, in depth studies related to alter-
native mechanisms of action must be performed with APD. Addi-
tionally, while computational methodologies are valuable tools,
even well validated methodologies can produce false positives. For
example, Degliesposti et al. (2009) designed and developed a
rigorous in silico pipeline to observe PM2 inhibition, yet still ob-
tained four false positives of thirty compounds tested. Further,
future APD could be useful for the antimalarial drug discovery
community as decoys or negative controls for in silico high-
throughput screening campaigns to identify PM2 inhibitors
(similar physicochemical properties, but structurally dissimilar to
APD) (Huang et al., 2006).
3.10. Target exploration of the hemozoin formation pathway
The compounds with both in vivo and in vitro antiplasmodial
activity against P. berghei and P. falciparum, respectively, were
further tested against the hemozoin formation drug target pathway
to understand the mechanism of action. The in vitro b-hematin
inhibition assay established by Sandlin et al. (2011) was utilized for
these three compounds (22, 23, and 25). Only compound 22 was
found to inhibit b-hematin formation with an IC50 of 80.7 ± 1.7 mM
(Table 4). The afﬁnity of compound 22 for the m-oxo dimer form of
heme was shown through a binding curve with 22. When
compared to positive and negative control compound binding
curves (chloroquine and pyrimethamine, respectively), compound
22 exhibited afﬁnity resembling that of chloroquine
(Supplementary Data Fig. 2), a known hemozoin inhibitor. To
further explore the mechanism of action of compound 22, target
validation of the hemozoin formation pathway was conducted in a
culture of parasites. Examination of the three species of parasitic
heme (host ingested hemoglobin, intracellular free heme, and
hemozoin) revealed that the primary mode of action for compound
22 is not through hemozoin formation inhibition. Despite a decline
in parasite viability with increasing concentrations of compound,
the levels of free heme and hemozoin remained constant. There-
fore, the hemozoin formation pathway is not the predominant
mode of death when a culture of parasite is subjected to compound
22. While our in vitro assay used has previously resulted in the
highest hit rate and lowest false positive rates amongst other b-
hematin inhibition assays (Sandlin et al., 2014), there are still limits.
This plate assay closely resembles the biological environment of the
site of hemozoin formation, but target validation is vital to ensure
that the in vitro results translate to a parasite culture. One hy-
pothesis is that compound 22 inhibits hemozoin formation; how-
ever, secondarily to amore potentmechanism of action, causing the
levels of heme species to remain unchanged.
3.11. Three-dimensional pharmacophore model for new APD
A pharmacophore for arylamino alcohols is deﬁned as the
general structural requirements necessary for its antiplasmodial
activity (Fig. 1). This deﬁnition led us to ask: Are APD like any of the
historical arylamino alcohols? Do they share the same pharmaco-
phore? Based on in vitro, in vivo, and target exploration results, we
investigated the structural similarities and differences between
APD and CAA (quinine, meﬂoquine, lumefantrine, and halofantrine)
using 3D pharmacophore models. First, we constructed andanalyzed an in silico 3D pharmacophore model for the new APD.
Second, the resulting 3D pharmacophore model for APD was
compared with the in silico 3D pharmacophore model of CAA in
order to identify common features between APD and CAA.
Although two-dimensional (2D) pharmacophore models could be
inferred from Fig. 1, these models lack 3D arrangements (3D con-
ditional patterns), which are important at the moment to study
potential modes of union between ligands and macromolecules.
Two 3D pharmacophore models (R and S conﬁguration) were
generated for APD (Fig. 3a), resulting in similar features, but a
different 3D arrangement of the naphthyl group. Then, bothmodels
were aligned and the pharmacophoric features were merged into a
unique model, creating a consensus pharmacophore (Fig. 3b). The
ﬁnal model consisted of four HPF, one PIF, two ARF, seven HBAF, and
one HBDF. Due to the absence of the triﬂuoromethyl group in
compound 23, these substituent features were presented as
optional (dot lines) in the model. A detailed summary of the
pharmacophoric features for each compound is presented in
Supplementary Data Fig. 3. A consensus pharmacophore model for
CAA was also generated (Fig. 3b), consisting of four HPF, one PIF,
two ARF, one HBDF, and one HBAF. Two HPF were shown as
optional since meﬂoquine and quinine do not share identical fea-
tures with halofantrine and lumefantrine. Additionally, one ARF
was shown as optional due to lumefantrine not sharing this feature
with quinine, halofantrine, and meﬂoquine.
The consensus pharmacophore models for APD and CAA were
aligned and the common features were extracted (Fig. 3b),
including two HPF, one PIF, one ARF, one HBDF, and one HBAF. All
six features weremandatory in APD and CAA (no optional features).
Our ﬁndings are in agreement with the general description that
Bhattacharjee et al. (1996) reported for the arylamino alcohol
chemotype (Fig. 1). Speciﬁcally for APD, these common features are
observed in the hydrophobic (naphthyl and phenyl system) and the
amine region of the scaffold; however, APD exhibited nine differ-
ences in comparison with CAA (two HPF, one ARF, and six HBAF).
These pharmacophore differences may explain the lack of inhibi-
tionwith the PM2 enzyme and hemozoin pathway. Thus, only a 40%
(6/15) of similarity between APD and CAA was observed at the
pharmacophore level.
4. Conclusions
This manuscript has shown the synthesis, racemic separation, in
silico drug-likeness studies, in vitro evaluation against chloroquine
sensitive (F32 and D6) and multidrug resistant (FCR-3 and C235)
strains of P. falciparum, cytotoxicity (VERO), in silico metabolism
studies, genotoxicity, in vivo efﬁcacy in P. berghei mouse model,
target exploration, and pharmacophore modeling of new APD.
This work led to the identiﬁcation of four promising compounds
(22, 23, 24, and 25) that exhibit values of antiplasmodial activity
below 0.5 mM (FCR-3), appropriate drug-likeness proﬁle, adequate
selectivity index (37  SI  244), and absence of genotoxicity.
In vivo efﬁcacy in P. berghei mouse model showed APD 22, 23, and
25 as promising candidates. Notably, compound 22 displayed
excellent parasitemia reduction (98 ± 1%) and complete cure with
all treated mice surviving through the entire 21-day period with no
signs of toxicity. Additionally, compounds 22 and 23 showed potent
antimalarial activity in chloroquine sensitive and multidrug resis-
tant strains (D6 IC50  0.19 mM, C235 IC50  0.28 mM). Target
exploration was performed in order to establish a possible mech-
anism of action; however, both the PM2 enzyme and the hemozoin
inhibition pathway were ruled out as primary targets for APD.
Comparison of 3D pharmacophore models indicated only a 40%
similarity between APD and CAA. This similarity consisted of two
HPF, one PIF, one ARF, one HBDF, and one HBAF.
Fig. 3. Three-dimensional pharmacophore model for new APD: (a) 3D pharmacophore models for APD; (b) Consensus pharmacophore models for APD and CAA, and its common
features.
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in vivo efﬁcacy values, but also exhibited agreement between
in vitro and in vivo studies. This last point is important due to the
large number of potent antimalarial compounds reported in the
literature that are only efﬁcacious at in vitro and will no longer
proceed along the drug discovery pipeline. APD are promising
compounds as new antimalarial therapeutics not only for their
particular unexplored chemotype, but also for their unknown
mechanism of action, which we found to differ from chloroquine or
classical amino alcohols. Further optimization of the scaffold must
be done through complementary SAR, mechanistic, and pharma-
cology studies.
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